{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T12:09:12Z","timestamp":1788869352183,"version":"build-2803163510"},"reference-count":36,"publisher":"Elsevier BV","issue":"1-2","license":[{"start":{"date-parts":[[2009,12,1]],"date-time":"2009-12-01T00:00:00Z","timestamp":1259625600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2009,12,1]],"date-time":"2009-12-01T00:00:00Z","timestamp":1259625600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2009,12,1]],"date-time":"2009-12-01T00:00:00Z","timestamp":1259625600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2009,12,1]],"date-time":"2009-12-01T00:00:00Z","timestamp":1259625600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2009,12,1]],"date-time":"2009-12-01T00:00:00Z","timestamp":1259625600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2009,12,1]],"date-time":"2009-12-01T00:00:00Z","timestamp":1259625600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2009,12,1]],"date-time":"2009-12-01T00:00:00Z","timestamp":1259625600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100002811","name":"Cathay General Hospital","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002811","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004700","name":"Taipei Medical University","doi-asserted-by":"publisher","award":["93 CGH-TMU-13"],"award-info":[{"award-number":["93 CGH-TMU-13"]}],"id":[{"id":"10.13039\/501100004700","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100010613","name":"Taipei Medical University Hospital","doi-asserted-by":"publisher","award":["95 TMUH-TMU-07"],"award-info":[{"award-number":["95 TMUH-TMU-07"]}],"id":[{"id":"10.13039\/501100010613","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jns-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the Neurological Sciences"],"published-print":{"date-parts":[[2009,12]]},"DOI":"10.1016\/j.jns.2009.09.007","type":"journal-article","created":{"date-parts":[[2009,9,28]],"date-time":"2009-09-28T04:09:19Z","timestamp":1254110959000},"page":"64-68","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":32,"title":["Methylenetetrahydrofolate reductase polymorphisms and plasma homocysteine in levodopa-treated and non-treated Parkinson's disease patients"],"prefix":"10.1016","volume":"287","author":[{"given":"Rey-Yue","family":"Yuan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jau-Jiuan","family":"Sheu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jia-Ming","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chaur-Jong","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ing-Jy","family":"Tseng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chun-Sum","family":"Ho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ching-Ying","family":"Yeh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ya-Lin","family":"Hung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tsuey-Ru","family":"Chiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jns.2009.09.007_bib1","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1016\/S0140-6736(98)11058-9","article-title":"Homocysteine and vascular disease","volume":"354","author":"Hankey","year":"1999","journal-title":"Lancet"},{"key":"10.1016\/j.jns.2009.09.007_bib2","doi-asserted-by":"crossref","first-page":"2007","DOI":"10.1056\/NEJMoa011613","article-title":"Plasma homocysteine as a risk factor for dementia and Alzheimer's disease","volume":"346","author":"Seshadri","year":"2002","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jns.2009.09.007_bib3","first-page":"527","article-title":"Sulfate and cysteine levels in the plasma of patients with Parkinson's disease","volume":"16","author":"Allain","year":"1995","journal-title":"Neurotoxicology"},{"key":"10.1016\/j.jns.2009.09.007_bib4","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1007\/s004150050292","article-title":"Hyperhomocysteinaemia in Parkinson's disease","volume":"245","author":"Kuhn","year":"1998","journal-title":"J Neurol"},{"key":"10.1016\/j.jns.2009.09.007_bib5","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1159\/000007984","article-title":"Elevated plasma levels of homocysteine in Parkinson's disease","volume":"40","author":"Kuhn","year":"1998","journal-title":"Eur Neurol"},{"key":"10.1016\/j.jns.2009.09.007_bib6","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/S0140-6736(99)01660-8","article-title":"Nigral endothelial dysfunction, homocysteine, and Parkinson's disease","volume":"354","author":"Muller","year":"1999","journal-title":"Lancet"},{"key":"10.1016\/j.jns.2009.09.007_bib7","doi-asserted-by":"crossref","first-page":"E1","DOI":"10.1038\/ncpneuro0527","article-title":"Neurotoxicity of levodopa: treatment-associated homocysteine increase","volume":"3","author":"Muller","year":"2007","journal-title":"Nat Clin Pract Neuro"},{"key":"10.1016\/j.jns.2009.09.007_bib8","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.1093\/clinchem\/47.6.1102","article-title":"Plasma homocysteine and L-DOPA metabolism in patients with Parkinson disease","volume":"47","author":"Blandini","year":"2001","journal-title":"Clin Chem"},{"key":"10.1016\/j.jns.2009.09.007_bib9","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/S0304-3940(01)01972-3","article-title":"Decrease of methionine and S-adenosylmethionine and increase of homocysteine in treated patients with Parkinson's disease","volume":"308","author":"Muller","year":"2001","journal-title":"Neurosci Lett"},{"key":"10.1016\/j.jns.2009.09.007_bib10","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1038\/ng0595-111","article-title":"A candidate genetic risk factor for vascular disease: a common mutation in methylenetetrahydrofolate reductase","volume":"10","author":"Frosst","year":"1995","journal-title":"Nat Genet"},{"key":"10.1016\/j.jns.2009.09.007_bib11","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1016\/S0021-9150(00)00671-7","article-title":"The 1298A\u2212>C polymorphism in methylenetetrahydrofolate reductase (MTHFR): in vitro expression and association with homocysteine","volume":"156","author":"Weisberg","year":"2001","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.jns.2009.09.007_bib12","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1093\/qjmed\/hcg039","article-title":"5, 10-Methylenetetrahydrofolate reductase 677C\u2212>T and 1298A\u2212>C mutations are genetic determinants of elevated homocysteine","volume":"96","author":"Castro","year":"2003","journal-title":"QJM"},{"key":"10.1016\/j.jns.2009.09.007_bib13","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1006\/mgme.1998.2714","article-title":"A second genetic polymorphism in methylenetetrahydrofolate reductase (MTHFR) associated with decreased enzyme activity","volume":"64","author":"Weisberg","year":"1998","journal-title":"Mol Genet Metab"},{"key":"10.1016\/j.jns.2009.09.007_bib14","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1212\/WNL.55.3.437","article-title":"Plasma homocysteine and MTHFR C677T genotype in levodopa-treated patients with PD","volume":"55","author":"Yasui","year":"2000","journal-title":"Neurology"},{"key":"10.1016\/j.jns.2009.09.007_bib15","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1212\/WNL.56.2.281","article-title":"Plasma homocysteine and MTHFR C677T genotype in levodopa-treated patients with PD","volume":"56","author":"Kuhn","year":"2001","journal-title":"Neurology"},{"key":"10.1016\/j.jns.2009.09.007_bib16","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1212\/WNL.56.2.281","article-title":"Plasma homocysteine and MTHFR C677T genotype in levodopa-treated patients with PD","volume":"56","author":"Brattstrom","year":"2001","journal-title":"Neurology"},{"key":"10.1016\/j.jns.2009.09.007_bib17","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1007\/978-3-7091-0579-5_2","article-title":"MTHFR C677T polymorphism, folic acid and hyperhomocysteinemia in levodopa treated patients with Parkinson's disease","author":"Woitalla","year":"2004","journal-title":"J Neural Transm Suppl"},{"key":"10.1016\/j.jns.2009.09.007_bib18","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.neulet.2006.05.040","article-title":"Hyperhomocysteinemia and methylenetetrahydrofolate reductase polymorphism in patients with Parkinson's disease","volume":"404","author":"Religa","year":"2006","journal-title":"Neurosci Lett"},{"key":"10.1016\/j.jns.2009.09.007_bib19","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.jns.2006.05.040","article-title":"Homocysteine serum levels and MTHFR C677T genotype in patients with Parkinson's disease, with and without levodopa therapy","volume":"248","author":"Todorovic","year":"2006","journal-title":"J Neurol Sci"},{"key":"10.1016\/j.jns.2009.09.007_bib20","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1002\/mds.22227","article-title":"Homocysteine is not associated with global motor or cognitive measures in nondemented older Parkinson's disease patients","volume":"24","author":"Camicioli","year":"2009","journal-title":"Mov Disord"},{"key":"10.1016\/j.jns.2009.09.007_bib21","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1007\/s12017-007-8006-x","article-title":"Effect of MTHFR polymorphisms on hyperhomocysteinemia in levodopa-treated Parkinsonian patients","volume":"9","author":"Caccamo","year":"2007","journal-title":"Neuromolecular Med"},{"key":"10.1016\/j.jns.2009.09.007_bib22","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1136\/jnnp.55.3.181","article-title":"Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases","volume":"55","author":"Hughes","year":"1992","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1016\/j.jns.2009.09.007_bib23","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/S0169-328X(02)00672-1","article-title":"Association of the C677T and A1298C polymorphisms in the 5, 10 methylenetetrahydrofolate reductase gene in patients with migraine risk","volume":"111","author":"Kara","year":"2003","journal-title":"Brain Res Mol Brain Res"},{"key":"10.1016\/j.jns.2009.09.007_bib24","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1212\/01.WNL.0000055899.24594.8E","article-title":"Effect of L-dopa on plasma homocysteine in PD patients: relationship to B-vitamin status","volume":"60","author":"Miller","year":"2003","journal-title":"Neurology"},{"key":"10.1016\/j.jns.2009.09.007_bib25","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.parkreldis.2004.07.008","article-title":"Plasma homocysteine levels in Parkinson's disease: role of antiparkinsonian medications","volume":"11","author":"Zoccolella","year":"2005","journal-title":"Parkinsonism Relat Disord"},{"key":"10.1016\/j.jns.2009.09.007_bib26","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1034\/j.1600-0404.2003.00135.x","article-title":"Levodopa-induced hyperhomocysteinaemia in Parkinson's disease","volume":"108","author":"Yasui","year":"2003","journal-title":"Acta Neurol Scand"},{"key":"10.1016\/j.jns.2009.09.007_bib27","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.1002\/mds.20253","article-title":"Modest increase in plasma homocysteine follows levodopa initiation in Parkinson's disease","volume":"19","author":"O'Suilleabhain","year":"2004","journal-title":"Mov Disord"},{"key":"10.1016\/j.jns.2009.09.007_bib28","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1001\/archneur.61.5.633","article-title":"Levodopa elevates homocysteine: is this a problem?","volume":"61","author":"O'Suilleabhain","year":"2004","journal-title":"Arch Neurol"},{"key":"10.1016\/j.jns.2009.09.007_bib29","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1111\/j.1468-1331.2004.00973.x","article-title":"Hyperhomocysteinemia in L-dopa treated Parkinson's disease patients: effect of cobalamin and folate administration","volume":"12","author":"Lamberti","year":"2005","journal-title":"Eur J Neurol"},{"key":"10.1016\/j.jns.2009.09.007_bib30","doi-asserted-by":"crossref","first-page":"1941","DOI":"10.1212\/01.wnl.0000219815.83681.f7","article-title":"Vitamins and entacapone in levodopa-induced hyperhomocysteinemia: a randomized controlled study","volume":"66","author":"Postuma","year":"2006","journal-title":"Neurology"},{"key":"10.1016\/j.jns.2009.09.007_bib31","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/S0022-510X(02)00353-2","article-title":"Hypertrophy of IMC of carotid artery in Parkinson's disease is associated with L-DOPA, homocysteine, and MTHFR genotype","volume":"207","author":"Nakaso","year":"2003","journal-title":"J Neurol Sci"},{"key":"10.1016\/j.jns.2009.09.007_bib32","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1001\/archneur.60.1.59","article-title":"Elevated plasma homocysteine levels in patients treated with levodopa. Association with vascular disease","volume":"60","author":"Rogers","year":"2003","journal-title":"Arch Neurol"},{"key":"10.1016\/j.jns.2009.09.007_bib33","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1001\/archneur.61.6.865","article-title":"Elevated plasma homocysteine level in patients with Parkinson disease: motor, affective, and cognitive associations","volume":"61","author":"O'Suilleabhain","year":"2004","journal-title":"Arch Neurol"},{"key":"10.1016\/j.jns.2009.09.007_bib34","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1515\/CCLM.2005.193","article-title":"Plasma homocysteine levels in L-dopa-treated Parkinson's disease patients with cognitive dysfunctions","volume":"43","author":"Zoccolella","year":"2005","journal-title":"Clin Chem Lab Med"},{"key":"10.1016\/j.jns.2009.09.007_bib35","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1179\/016164106X110445","article-title":"Plasma homocysteine levels in patients treated with levodopa: motor and cognitive associations","volume":"28","author":"Ozer","year":"2006","journal-title":"Neurol Res"},{"key":"10.1016\/j.jns.2009.09.007_bib36","doi-asserted-by":"crossref","first-page":"1607","DOI":"10.1515\/CCLM.2007.337","article-title":"Management of L-Dopa related hyperhomocysteinemia: catechol-O-methyltransferase (COMT) inhibitors or B vitamins? Results from a review","volume":"45","author":"Zoccolella","year":"2007","journal-title":"Clin Chem Lab Med"}],"container-title":["Journal of the Neurological Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022510X09008491?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022510X09008491?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,20]],"date-time":"2025-09-20T15:38:21Z","timestamp":1758382701000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022510X09008491"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,12]]},"references-count":36,"journal-issue":{"issue":"1-2","published-print":{"date-parts":[[2009,12]]}},"alternative-id":["S0022510X09008491"],"URL":"https:\/\/doi.org\/10.1016\/j.jns.2009.09.007","relation":{},"ISSN":["0022-510X"],"issn-type":[{"value":"0022-510X","type":"print"}],"subject":[],"published":{"date-parts":[[2009,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Methylenetetrahydrofolate reductase polymorphisms and plasma homocysteine in levodopa-treated and non-treated Parkinson's disease patients","name":"articletitle","label":"Article Title"},{"value":"Journal of the Neurological Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jns.2009.09.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2009 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}